Daclizumab treatment for multiple sclerosis

Pharmacotherapy

Volumn 29, Issue 2, 2009, Pages 227-235

  Kim, Sylvia E ^a  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

Author keywords

Daclizumab; Monoclonal antibodies; MS; Multiple sclerosis

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DOXYCYCLINE; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; OKT 3; PLACEBO; RITUXIMAB;

ACUTE LEUKEMIA; ADD ON THERAPY; ANEMIA; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BILIRUBIN BLOOD LEVEL; BLOOD BRAIN BARRIER; BREAST TENDERNESS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONSTIPATION; CROHN DISEASE; DEPRESSION; DISEASE ACTIVITY; DISEASE COURSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; FEVER; HEADACHE; HEREDITY; HUMAN; INJECTION SITE INFECTION; KIDNEY ALLOGRAFT REJECTION; LEUKOPENIA; LYMPHADENOPATHY; LYMPHOCYTE; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NEPHROLITHIASIS; NERVOUS SYSTEM INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PARESTHESIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYELONEPHRITIS; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SIDE EFFECT; SINUSITIS; SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 59949086807     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.2.227     Document Type: Review

References (91)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13): 938-52.
2. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31.
3. Kantarci OH. Genetics and natural history of multiple sclerosis. Semin Neurol 2008: 28(1): 7-16.
4. National Multiple Sclerosis Society. Who gets MS? Available from www.nationalmssociety.org/about-multiple-sclerosis/ who- gets-ms/index.aspx. Accessed January 15, 2008.
5. Vanderlocht J, Hellings N, Hendriks JJ, Stinissen P. Current trends in multiple sclerosis research: an update on pathogenic concepts. Acta Neurol Belg 2006;106(4): 180-90.
6. Aktas O, Waiczies S, Zipp F. Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets. J Neuroimmunol 2007;184: 17-26.
7. Hohlfeld R, Wekerle H. Drug insight: using monoclonal antibodies to treat multiple sclerosis. Nat Clin Pract Neurol 2005;1(1): 34-44.
8. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199(7): 971-9.
9. Hoffmann-La Roche Inc. Zenapax (daclizumab) package insert. Nutley, NJ; 2005.
10. Emre S, Gondolesi G, Polat K, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001;7(3): 220-5.
11. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute a graft-versus-host disease with humanized anti-tac: an antibody that binds to the interleukin-2 receptor. Blood 1994;84(4): 1320-7.
12. Waldmann TA. Anti-IL-2 receptor monoclonal antibody (anti- Tac) treatment of T cell lymphoma. Important Adv Oncol 1994;8: 131-41.
13. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U SA1999;96: 7462-6.
14. Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti- interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003;21(3): 283-93. (Erratum in J Autoimmun 2004;23(1): 93.)
15. Bielekova B, Richert N, Howard T, et al. Humanized anti- CD25 ( daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proc Natl Acad Sci U S A 2004;101(23): 8705-8. (Erratum in Proc Natl Acad Sci U S A 2004;101(50): 17565.)
16. bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006;103(15): 5941-6.
17. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004;56: 864-7.
18. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007;69(8): 785-9.
19. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 1996;46(4): 907-11.
20. Kieseier BC, Hartung H. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003;23: 133-45.
21. De Jager PL, Hafler DA. New therapeutic approaches for multiple sclerosis. Annu Rev Med 2007;58: 417-32.
22. Wingerchuk DM. Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol 2008;28: 56-68.
23. Polman CH, Uitdehaag BM. New and emerging treatment options for multiple sclerosis. Lancet Neurol 2003;2(9): 563-6.
24. Vaknin-Dembinsky A, Weiner HL. Relatio nship o f immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy. J Neurol Sci 2007;259: 90-4.
25. Lassmann H. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 2007;7: 239-44.
26. Bakshi R, Hutton GJ, Miller JR, Radue EW. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology 2004;63(suppl5): S3-11.
27. Zivadinov R, Bakshi R. Role of MRI in multiple sclerosis I: inflammation and lesions. Front Biosci 2004;9: 665-83.
28. Zivadinov R, Bakshi R. Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. Front Biosci 2004;9: 647-64.
29. Bruck W, Bitsch A, Kolenda H, Bruck Y, Strefel H, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42: 783-93.
30. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria" Ann Neurol 2005;58: 840-6.
31. Rashid W, Miller D. Recent advances in neuroimaging of multiple sclerosis. Semin Neurol 2008;28: 46-55.
32. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000;355: 735-40.
33. Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006;58: 640-56.
34. Pavlou AK, Belsey MJ. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 2005;59: 389-96.
35. Smith BT. Concepts in immunology and immunotherapeutics, 4th ed. Bethesda, MD: American Society of Health-System Pharmacists, 2008;25-48.
36. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256: 495-7.
37. Muraro PA, Bielekova B. Emerging therapies for multiple sclerosis. Neurotherapeutics 2007;4: 676-92.
38. Bachmann MF, Oxenius A. Interleukin 2: from immuno- stimulation to immunoregulation and back again. EMBO Rep 2007;8(12): 1142-8.
39. Cornish GH, Sinclair LV, Cantrell DA. Differential regulation of T-cell growth by IL-1 and IL-15. Blood 2006;108: 600-8.
40. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008;26: 453-79.
41. Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol 2002;22(2): 51-6.
42. bright regulatory NK cells in patient with active uveitis. J Immunol 2005;174(9): 5187-91. (Erratum in J Immunol 2005;175(5): 3447.)
43. Airas L, Saraste M, Rinta S, et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol 2007; 151: 235-43.
44. bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007;28(3): 121-6.
45. Snyder JT, Shen J, Azmi H, Hou J, Fowler DH, Ragheb JA. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on c ell divisio n and Th1 /Th2 cytokine production. Blood 2007;109(12): 5399-406.
46. Montalban X, Wynn D, Kaufman M, on behalf of CHOICE Investigators. Daclizumab in patients with active, relapsing multiple sclerosis on concurrent interferon-beta therapy: week 24 data-phase II (CHOICE) study [slide presentation]. 2007. Available from www.pdl.com/documents/ectrims-2007-pdf. pdf. Accessed December 2, 2007.
47. Biogen Idec Inc and PDL BioPharma, Inc. Phase 2 data show daclizumab significantly reduced multiple sclerosis lesions in patients receiving interferon beta therapy [press release]. October 11, 2007. Available from www.biogenidec.comr/news/PR-189.pdf. Accessed December 2, 2007.
48. Martin R. Humanized anti-CD25 antibody treatment with dac lizumab in multiple sclero sis. Neuro de ge ner Dis 2008;5: 23-6.
49. Gonsette RE. Compared benefit of approved and experimental immuno suppressive therapeutic appro aches in multiple sclerosis. Expert Opin Pharmacother 2007;8(8): 1103-16.
50. EMD Serono, Inc. Rebif (interferon beta-1a) package insert. Rockland, MA; 2008.
51. Biogen Idec Inc. Avonex (interferon beta-1a) package insert. Cambridge, MA; 2006.
52. Bayer Healthcare Pharmaceuticals Inc. Betaseron (interferon beta-1b) package insert. Wayne, NJ; 2007.
53. Teva Neuroscience, Inc. Co paxone ( glatiramer acetate) package insert. Kansas City, MO; 2007.
54. EMD Serono, Inc. Novantrone (mitoxantrone) package insert. Rockland, MA; 2006.
55. Biogen Idec Inc. Tysabri ( natalizumab) package insert. Cambridge, MA; 2008.
56. Wolinsky JS. Rational therapy for relapsing multiple sclerosis. Lancet Neurol 2003;2: 271-2.
57. Sorensen S. The gap between effect of drugs and effectiveness of treatments. J Neurol Sci 2007;259: 128-32.
58. Ruggieri M, Avolio C, Livrea P, Trojano M. Glatiramer acetate in multiple sclerosis: a review. CNS Drug Rev 2007;13(2): 178-91.
59. PRISMS (Prevention of Relapses and Disability by Interferon Beta-la Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind place bo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352(9139): 1498-504. (Erratum in Lancet 1999;353(9153): 678.)
60. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the multiple sclerosis collaborative research group (MSCRG). Ann Neurol 1996;39: 285-94.
61. Comi G, Filippi M, Wolinsky JS, et al, for the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49: 290-7.
62. SPECTRIMS (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS) Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS. Neurology 2001;56: 1496-504.
63. Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. The North American study group on interferon beta-1b in secondary progressive MS. Neurology 2004;63: 1788-95.
64. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352: 1491-7.
65. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial: the promise trial study group. Ann Neurol 2007;61: 14-24.
66. Bayer HealthCare AG. Therapy of multiple sclerosis BEYOND study: results do not support regulatory filing for Betaferon® 500 mcg [press release]. October 29, 2007. Available from www.betaseron.com/patients/pdfs/ BEYOND%20Study%20News %20Release.pdf. AccessedJuly 2, 2008.
67. Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004;63(suppl 6): S15-18.
68. Fidler JM, DeJoy SQ, Gibbons JJ Jr. Selective immuno- modulation by the antineoplastic agent mitoxantrone, I: suppression of B lymphocyte function. J Immunol 1986;137: 727-32.
69. Fidler JM, DeJoy SQ, Smith FR III, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone, II: no nspec ific adherent suppressor cells de rived from mitoxantrone-treated mice. J Immunol 1986;136: 2747-54.
70. Putzki N, Kumar M, Vago S, Kreutzfelder E, Limmroth V. Mitoxantrone treatment leads to a persistent selective decrease of the B cell count in patients with multiple sclerosis [abstract]. Neurology 2006;66(suppl 2): A370, abstract P06.160.
71. Watson CM, Davison AN, Baker D, O'Neil JK, Turk JL. Suppre ssion o f de myelination by mitoxantrone. Int J Immunopharmacol 1991;13(7): 923-30.
72. Hartung H, G onsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double- blind, randomized, multicentre trial. Lancet 2002;360: 2018-25.
73. Jeffery DR, Herndon R. Review of mitoxantrone in the treatment of multiple sclerosis. Neurology 2004; 63(suppl 6): S19-24.
74. Studie;ve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 2007;13(1): 79-94.
75. Stüve O, Marta CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59: 743-7.
76. Polman CH, O'Connor PW, Havrdova E, et al, for the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354: 899-910.
77. Rudick RA, Stuart WH, Calabresi PA, et al, for the SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354: 911-23.
78. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353: 369-74.
79. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353: 375-81.
80. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353: 362-8.
81. U.S. Food and Drug Administration. FDA approves resumed marketing of Tysabri under a special distribution program [press release]. June 5-6, 2006. Available from www.fda.gov/bbs/topics/NEWS/2006/NEW01380.html. Accessed November 2, 2007.
82. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N EnglJ Med 2006;354: 924-33.
83. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BMJ, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab treated MS patient. Neurology 2007;69: 1-2.
84. Costello F, Sẗve O, Weber MS, Zamvil SS, Frohman E. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol 2007;20(3): 281-5.
85. Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008;14(5): 663-70.
86. Minagar A, Alexander JS, Schwendimann RN, et al. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neuro l 2008;656(2): 199-204.
87. Jeffery DR. Use of combination therapy with immuno-modulators and immunosuppressants in treating multiple sclerosis. Neurology 2004;63: S41-6.
88. Stuart WH, Vermersch P. Concomitant therapy for multiple sclerosis. Neurology 2004;63(suppl 5): S28-34.
89. Tullman MJ, Lublin FD. Combination therapy in multiple sclerosis. Curr Neurol Neurosci Rep 2005;5: 245-8.
90. Martinelli V. Combination therapy. Neurol Sci 2006; 27: S350-4.
91. National Multiple Sclerosis Society. Clinical trials in multiple sclerosis 2008: planned, in progress, recently completed. Available from www.nationalmssociety.org/research/clinical-trials/download.aspx?id=224. Accessed June 22, 2008.